Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.61 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SHBG | P04278 | 2/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334388 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL13301261 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL9965232 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL4584277 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| Sulfuric Acid SCHEMBL9022915 | 0.94 | CYP19A1 (0.88) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| Sulfuric Acid SCHEMBL7467213 | 0.94 | CYP19A1 (0.88) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL20166975 | 0.82 | CYP19A1 (0.70) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL1460891 | 0.82 | CYP19A1 (0.70) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL16659742 | 0.82 | CYP19A1 (0.69) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL11648596 | 0.80 | CYP19A1 (0.67) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388003-B2 | Δ15-D-Homosteroids with androgenic action | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | claimed |
| EP-1658306-A1 | DELTA 15 -D-HOMOSTEROIDS HAVING AN ANDROGENIC EFFECT | Schering AG (DE) | 2006-05-24 | — | — | EP | claimed |
| US-20050131076-A1 | Delta15-D-Homosteroids with androgenic action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2005021573-A1 | Δ15-D-HOMOSTEROIDS HAVING AN ANDROGENIC EFFECT | SCHERING AG (DE) | 2005-03-10 | — | — | WO | claimed |
| US-5714481-A | ADMINISTERING TO MAMMALIAN HOST A GLUCOSE-6-PHSOPHATE DEHYDROGENASE INHIBITOR, ANTICARCINOGENIC, ANTIOBASITY, ANTI-HYPERGLYCEMIC, ANTIAGING, ANTICHOLESTEROL AND ANTI-AUTOIMMUNE AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | claimed |
| EP-0066001-A1 | Pharmaceutical compositions containing androstenes | Laboratoire Théramex (MC) | 1982-12-08 | — | — | EP | claimed |
| WO-2023056892-A1 | TECHNICAL STAINS COMPRISING DNA | NOVOZYMES A/S (DK) | 2023-04-13 | — | — | WO | disclosed |
| US-11046728-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3021852-B1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190298646-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | INITIUM INNOVATIONS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20180215779-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215779-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20160152658-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| EP-0066001-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANDROSTENES | Laboratoire Théramex (MC) | 1986-05-14 | — | — | EP | disclosed |
| EP-0066001-A1 | Pharmaceutical compositions containing androstenes | Laboratoire Théramex (MC) | 1982-12-08 | — | — | EP | disclosed |
| EP-0066001-A1 | Pharmaceutical compositions containing androstenes | Laboratoire Théramex (MC) | 1982-12-08 | — | — | EP | disclosed |
| US-4177190-A | Diamino-androstanes and a process for the preparation of the said compounds | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1979-12-04 | — | — | US | disclosed |
| US-4150126-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS AND ANIBODY INHIBITORS | AKTIEBOLAGET LEO (SE) | 1979-04-17 | — | — | US | disclosed |
| US-4110326-A | STEROIDS, CURARE-TYPE | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1978-08-29 | — | — | US | disclosed |
| US-4101545-A | NEUROMUSCULAR BLOCKING AGENTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131076-A1 | Delta15-D-Homosteroids with androgenic action | CYP17A1, HSD3B2, HSD3B1 | CYP19A1 16/4885AKR1B10 84/4885AKR1B1 81/4885 |
| US-11046728-B2 | Neuroactive steroids, compositions, and uses thereof | ADRA1B, AVPR1B, ADRA2B | CYP19A1 117/4885AKR1B10 301/4885AKR1B1 204/4885 |
| US-20160152658-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRA1B, AVPR1B, ADRA2B | CYP19A1 123/4885AKR1B10 313/4885AKR1B1 208/4885 |
| US-20180215779-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRA1B, AVPR1B, ADRA2B | CYP19A1 117/4885AKR1B10 301/4885AKR1B1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.